Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
18
03
2020
accepted:
04
06
2020
revised:
12
05
2020
pubmed:
27
6
2020
medline:
16
3
2021
entrez:
27
6
2020
Statut:
ppublish
Résumé
With the recent approval of the combinations of axitinib with the immune checkpoint inhibitor (ICI) pembrolizumab or avelumab for first-line treatment of advanced renal cell carcinoma, guidance on how to distinguish between immune-related adverse events (AEs) caused by ICI versus axitinib-related AEs is necessary to optimise therapy with axitinib-ICI combinations. The recommendations here are based on (1) systematic review of published evidence, (2) discussion among experts in the field and (3) a survey to obtain expert consensus on specific measures for therapy management with the combinations axitinib/avelumab and axitinib/pembrolizumab. The experts identified areas of AEs requiring unique management during treatment with axitinib-ICI combinations that were not covered by current recommendations. Diarrhoea, hepatic toxicity, fatigue and cardiovascular AEs were found to be applicable to such specialised management. Triage between immune-suppressive and supportive measures is a key component in therapy management. Clinical monitoring and experience with both classes of agents are necessary to manage this novel therapeutic approach. We focused on AEs with an overlap between axitinib and ICI therapy. Our recommendations address AE management of axitinib-ICI combinations with the aim to improve the safety of these therapies.
Identifiants
pubmed: 32587360
doi: 10.1038/s41416-020-0949-9
pii: 10.1038/s41416-020-0949-9
pmc: PMC7492460
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Immune Checkpoint Inhibitors
0
Axitinib
C9LVQ0YUXG
pembrolizumab
DPT0O3T46P
avelumab
KXG2PJ551I
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
898-904Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Pfizer (Pfizer Inc.)
ID : not applicable
Organisme : Pfizer (Pfizer Inc.)
ID : Not applicable
Références
Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103–2111 (2007).
doi: 10.1016/S0140-6736(07)61904-7
Hutson, T. E., Lesovoy, V., Al-Shukri, S., Stus, V. P., Lipatov, O. N., Bair, A. H. et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 14, 1287–1294 (2013).
doi: 10.1016/S1470-2045(13)70465-0
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584–3590 (2009).
doi: 10.1200/JCO.2008.20.1293
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).
doi: 10.1056/NEJMoa065044
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28, 1061–1068 (2010).
doi: 10.1200/JCO.2009.23.9764
Sternberg, C. N., Hawkins, R. E., Wagstaff, J., Salman, P., Mardiak, J., Barrios, C. H. et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur. J. Cancer 49, 1287–1296 (2013).
doi: 10.1016/j.ejca.2012.12.010
McDermott, D. G., Lee, J. L., Ziobro, M., Gafanov, R. A., Matveev, V. B., Suárez, C. et al. First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (NCC-RCC): results from KEYNOTE-427 cohort B. J. Clin. Oncol. 37, 546 (2019).
doi: 10.1200/JCO.2019.37.7_suppl.546
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).
doi: 10.1056/NEJMoa1510665
Vaishampayan, U. N., Schöffski, P., Ravaud, A., Borel, C., Peguero, J., Chaves, J. et al. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial. J. Immunother. Cancer 7, 275 (2019).
doi: 10.1186/s40425-019-0746-2
Dirkx, A. E., oude Egbrink, M. G., Castermans, K., van der Schaft, D. W., Thijssen, V. L., Dings, R. P. et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 20, 621–630 (2006).
doi: 10.1096/fj.05-4493com
Lapeyre-Prost, A., Terme, M., Pernot, S., Pointet, A. L., Voron, T., Tartour, E. et al. Immunomodulatory activity of VEGF in cancer. Int Rev. Cell Mol. Biol. 330, 295–342 (2017).
doi: 10.1016/bs.ircmb.2016.09.007
Liu, C., Workman, C. J. & Vignali, D. A. Targeting regulatory T cells in tumors. FEBS J. 283, 2731–2748 (2016).
doi: 10.1111/febs.13656
Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103–1115 (2019).
doi: 10.1056/NEJMoa1816047
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116–1127 (2019).
doi: 10.1056/NEJMoa1816714
de Velasco, G., Bex, A., Albiges, L., Powles, T., Rini, B. I., Motzer, R. J. et al. Sequencing and combination of systemic therapy in metastatic renal cell carcinoma. Eur. Urol. Oncol. 2, 505–514 (2019).
doi: 10.1016/j.euo.2019.06.022
ESMO Guidelines Committee. eUpdate—Renal cell carcinoma treatment recommendations. https://www.esmo.org/guidelines/genitourinary-cancers/renal-cell-carcinoma/eupdate-renal-cell-carcinoma-treatment-recommendations-2 . Accessed 9 March 2020 (2020).
Hahn, A. W., Klaassen, Z., Agarwal, N., Haaland, B., Esther, J., Ye, X. Y. et al. First-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur. Urol. Oncol. 2, 708–715 (2019).
doi: 10.1016/j.euo.2019.09.002
Kapadia, S., Hapani, S., Choueiri, T. K. & Wu, S. Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. Acta Oncol. 52, 1202–1212 (2013).
doi: 10.3109/0284186X.2013.782103
Albiges, L., Powles, T., Staehler, M., Bensalah, K., Giles, R. H., Hora, M. et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur. Urol. 76, 151–156 (2019).
doi: 10.1016/j.eururo.2019.05.022
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 36, 1714–1768 (2018).
doi: 10.1200/JCO.2017.77.6385
Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O. 3rd, Brogdon, C., Dadu, R. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 5, 95 (2017).
doi: 10.1186/s40425-017-0300-z
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 6, e1000100 (2009).
doi: 10.1371/journal.pmed.1000100
Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6, e1000097 (2009).
doi: 10.1371/journal.pmed.1000097
Haanen, J., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29, iv264–iv266 (2018).
doi: 10.1093/annonc/mdy162
Atkins, M. B., Plimack, E. R., Puzanov, I., Fishman, M. N., McDermott, D. F., Cho, D. C. et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 19, 405–415 (2018).
doi: 10.1016/S1470-2045(18)30081-0
Choueiri, T. K., Larkin, J., Oya, M., Thistlethwaite, F., Martignoni, M., Nathan, P. et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 19, 451–460 (2018).
doi: 10.1016/S1470-2045(18)30107-4
Abolhassani, A. R., Schuler, G., Kirchberger, M. C. & Heinzerling, L. C-reactive protein as an early marker of immune-related adverse events. J. Cancer Res Clin. Oncol. 145, 2625–2631 (2019).
doi: 10.1007/s00432-019-03002-1
Wang, Y., Pei, F., Wang, X., Sun, Z., Hu, C. & Dou, H. Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis. Int J. Clin. Exp. Pathol. 8, 12319–12332 (2015).
pubmed: 26722419
pmcid: 4680364
Chen, Y., Tortorici, M. A., Garrett, M., Hee, B., Klamerus, K. J. & Pithavala, Y. K. Clinical pharmacology of axitinib. Clin. Pharmacokinet. 52, 713–725 (2013).
doi: 10.1007/s40262-013-0068-3
Merck & Co Inc. KEYTRUDA® (pembrolizumab) for injection, for intravenous use, prescribing information. https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf . Accessed 18 May 2020 (2014).
EMD Serono Inc. BAVENCIO® (avelumab) injection, for intravenous use, prescribing information. https://www.emdserono.com/content/dam/web/corporate/non-images/country-specifics/us/pi/bavencio-pi.pdf . Accessed 10 September 2019 (2017).
O’Higgins, C. M., Brady, B., O’Connor, B., Walsh, D. & Reilly, R. B. The pathophysiology of cancer-related fatigue: current controversies. Support Care Cancer 26, 3353–3364 (2018).
doi: 10.1007/s00520-018-4318-7
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749–1755 (2016).
doi: 10.1056/NEJMoa1609214